Omega Diagnostics Group PLC
("Omega" or the "Company")
Grant of Options
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that its Remuneration Committee on 25 February 2014 awarded the following director share options:
|
|
Options granted 25 February 2014 |
|
Total options following grant |
Andrew Shepherd |
|
800,000 |
|
2,103,480 |
Kieron Harbinson |
|
640,000 |
|
1,408,987 |
Jag Grewal |
|
610,000 |
|
910,000 |
All options are awarded under the Company's EMI Share Option Scheme. The options have a three year vesting period, have been awarded at an exercise price of 30.5p (closing mid-market price on 24 February 2014) and after they are fully vested, there is a performance criteria that they cannot be exercised until the share price is at 50p or higher.
Contacts:
Omega Diagnostics Group PLC |
Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive |
|
Kieron Harbinson, Group Finance Director |
|
Jag Grewal, Group Sales and Marketing Director |
|
|
|
finnCap Ltd |
Tel: 020 7220 0500 |
Geoff Nash/Christopher Raggett (Corporate Finance) |
|
Stephen Norcross/Mia Gardner (Corporate Broking) |
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus |
Mob: 07980 541 893 |
Lianne Cawthorne |
Mob: 07584 391 303 |